Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Feb 20;90(8):e683-e689.
doi: 10.1212/WNL.0000000000004997. Epub 2018 Jan 26.

Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke

Nina A Hilkens  1 , Ale Algra  2 , L Jaap Kappelle  2 , Philip M Bath  2 , László Csiba  2 , Peter M Rothwell  2 , Jacoba P Greving  2 ; CAT Collaboration
Affiliations
Meta-Analysis

Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke

Nina A Hilkens et al. Neurology. .

Abstract

Objective: To study the early time course of major bleeding and its subtypes in patients with cerebral ischemia on dual and single antiplatelet therapy.

Methods: We performed a post hoc analysis on individual patient data from 6 randomized clinical trials (Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events [CAPRIE], Second European Stroke Prevention Study [ESPS-2], Management of Atherothrombosis With Clopidogrel in High-Risk Patients [MATCH], Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA], European/Australasian Stroke Prevention in Reversible Ischaemia Trial [ESPRIT], and Prevention Regimen for Effectively Avoiding Second Strokes [PRoFESS]) including 45,195 patients with a TIA or noncardioembolic ischemic stroke. We studied incidence rates of bleeding per antiplatelet regimen stratified by time from randomization (≤30, 31-90, 91-180, 181-365, >365 days). We calculated incidence rates per trial and pooled estimates with random-effects meta-analysis. We performed Poisson regression to assess differences between time periods with adjustment for age and sex.

Results: The incidence of major bleeding on aspirin plus clopidogrel and aspirin plus -dipyridamole was highest in the first 30 days, 5.8 and 4.9 per 100 person-years, respectively, and was significantly higher than at 31 to 90 days (rate ratio 1.98, 95% confidence interval 1.16-3.40 for aspirin plus clopidogrel; rate ratio 1.94, 95% confidence interval 1.24-3.03 for aspirin plus dipyridamole). Incidence rates on aspirin and clopidogrel monotherapy were 2.8 and 2.5 per 100 person-years, respectively, in the first 30 days, with no significant change over time. The time course was similar for gastrointestinal bleeds. There was no early excess of intracranial hemorrhage in patients on either dual or single antiplatelet therapy.

Conclusion: Dual antiplatelet therapy is associated with high early risks of major and gastrointestinal bleeding that decline after the first month in trial cohorts.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Time course of major bleeding per antiplatelet regimen (pooled estimates)
(A) Single antiplatelet therapy (APT), (B) dual APT, and (C) dipyridamole and placebo.
Figure 2
Figure 2. Time course of (A) gastrointestinal bleeding and(B) intracranial bleeding per antiplatelet regimen (pooled estimates)
APT = antiplatelet therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–1860. - PMC - PubMed
    1. Li L, Geraghty OC, Mehta Z, Rothwell PM; Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017;390:490–499. - PMC - PubMed
    1. Alberts MJ, Bhatt DL, Smith SC Jr, et al. . Risk factors and outcomes for patients with vascular disease and serious bleeding events. Heart 2011;97:1507–1512. - PubMed
    1. Berger JS, Bhatt DL, Steg PG, et al. . Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2011;162:98–105.e1. - PubMed
    1. Rothwell PM, Price JF, Fowkes FG, et al. . Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602–1612. - PubMed

Publication types

Substances